Compound description
What is Bromantane
Bromantane (ADK-709) is an atypical psychostimulant and actoprotector — a compound that raises physical and mental working capacity under demanding conditions without depleting the body's resources.
It was developed in the 1980s at the Institute of Pharmacology of the USSR Academy of Medical Sciences as an agent for maintaining performance under hypoxia, heat and intense physical load. It is a synthetic adamantane derivative — the same structural class as amantadine and memantine. In Russia it is registered as a medicine under the name Ladasten for the treatment of neurasthenia.
The mechanism that sets it apart from every classical stimulant. Bromantane does not block the dopamine transporter and does not bind its receptors: the IC₅₀ for dopamine transport is 3.56 μM versus 28.66 nM for sydnocarb — two orders of magnitude weaker, at concentrations unreachable at therapeutic doses. Instead it switches on de novo dopamine synthesis through genomic activation of two key enzymes: tyrosine hydroxylase (TH) and DOPA decarboxylase (AADC).
TH activation is epigenetic: a single dose produces a 2–2.5-fold rise in gene expression within 1.5–2 hours, via cytosine demethylation in the gene's promoter. TH is the rate-limiting enzyme of the entire dopamine pathway, so upregulating it widens the throughput of synthesis. This is why bromantane does not deplete neurotransmitter stores the way releasing agents do.
The epigenetic profile extends beyond dopamine. A single dose lowers histone deacetylase 1 (HDAC1) in the striatum and hippocampus and alters acetylation of histones H3 (Lys9) and H4 (Lys8). Proteomic mapping (2D electrophoresis with mass spectrometry) identified 13 proteins with altered expression — among them the axon-growth regulator DPYSL2/CRMP2 and the hypoxia-response protein HYOU1.
Neurotrophic support and plasticity. Bromantane raises BDNF and NGF expression and activates mitogen-activated kinases. In hippocampal slices it modulates long-term potentiation (LTP) — the cellular correlate of learning and memory.
The anxiolytic component has its own target. A screen of 588 genes showed that bromantane suppresses the GABA transporter 3 gene (GAT3/slc6a11): less GABA uptake means stronger inhibitory transmission. Hence the rare combination — stimulation without anxiety.
Clinical data. In a multicentre study (50–100 mg/day, 28 days), positive ratings reached 76.0% on CGI-S and 90.8% on CGI-I. The anti-asthenic effect appeared as early as day 3 and persisted a month after discontinuation. A separate placebo-controlled trial confirmed the combined psychostimulant and anxiolytic action. In healthy volunteers, a single 100 mg dose improved psychophysiological performance under mental fatigue with no behavioural toxicity — most markedly in stress-labile individuals.
The effect adapts to the person. An EEG study revealed an unusual property: the direction of action depends on the baseline EEG type. In people with a sthenic type bromantane acts mainly as a psychostimulant; in those with an asthenic type, as an anxiolytic.
No tolerance. Over a two-month course in rats, no tolerance developed, no dependence formed and no withdrawal syndrome was observed — unlike classical stimulants.
Convenient pharmacokinetics. Oral bioavailability ≈42%, onset at 1.5–2 h, elimination half-life ≈11.2 h in humans, duration of action 8–12 h — which supports once-daily dosing.
Directions beyond stimulation. Bromantane normalises T-lymphocyte subpopulations (CD4+/CD8+) under chronic stress and lowers IL-6 and IL-17. Canada's Algernon Pharmaceuticals repositioned the compound (code NP-160) as an antifibrotic agent: in a preclinical model of non-alcoholic steatohepatitis it produced a statistically significant reduction in fibrosis area, outperforming reference drugs. In 2025, data emerged on antiparkinsonian activity in a 6-OHDA model — pointing to neuroprotective potential.
Bromantane appears on the WADA prohibited list (section S6.A) — a status granted only to compounds with a confirmed effect on performance.
It is used as a research compound for studying stress-resistance mechanisms, dopaminergic neurotransmission, epigenetic regulation of gene expression and cognitive function.
